Bicalutamide: profile and news

Advances in Early-Stage Prostate Cancer 06 Mar 2006
...of 3 parallel clinical trials of men with either localized or locally advanced prostate cancer randomized to receive hormonal therapy with bicalutamide 150 mg ... - Medscape (subscription)

New Published Data[1] Show That Bicalutamide (Casodex) 150mg Plus ... Jan 31, 2006
New data published in the February 2006 edition of the British Journal of Urology International (BJUI) confirm that bicalutamide 150mg improves the chance of ... - Finanzen.net,

Bicalutamide 150mg Plus Radiotherapy Significantly Extends ... Feb 1, 2006
The 3rd Analysis of the Early Prostate Cancer Trial (EPC) Programme gives additional confirmation that bicalutamide 150mg is a proven treatment option for men ... - Medical News Today (press release),

The Early Prostate Cancer Trial And Adjuvant Anti-androgen Therapy ... Feb 25, 2006
It evaluated adjuvant bicalutamide in patients across the world that still had their standard care primary therapy: whether watchful-waiting, radiotherapy or ... - Medical News Today (press release),

ASCO 2006 Prostate Cancer Symposium - Session on The Treatment of ... Mar 3, 2006
Dr. See presented a podium abstract on adding bicalutamide 150mg to radiotherapy to significantly improve overall survival in men with locally advanced CaP. - UroToday,

Consiga la Gold Card American Express ahora Jan 31, 2006
...(PRN) - Millennium Announces Cash Tender Offer for Its 7.00% Senior Notes Due 2006 ... [+. PRN) - New Published Data[1] Show That Bicalutamide (Casodex) 150mg ... - Bolsamania.com,

(PRN) - Millennium Announces Cash Tender Offer for Its 7.00% ... Jan 31, 2006
...(PRN) - New Published Data[1] Show That Bicalutamide (Casodex) 150mg Plus Radiotherapy Significantly Extends Survival in Men With Locally Advanced Prostate ... - Bolsamania.com,

Other information

Indication
For treatment (together with surgery or LHRH analogue) of advanced prostatic cancer.

Pharmacology
Bicalutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. Bicalutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). Consequently, Bicalutamide blocks the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue. Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.

Mechanism Of Action
Bicalutamide competes with androgen for the binding of androgen receptors, consequently blocking the action of androgens of adrenal and testicular origin which stimulate the growth of normal and malignant prostatic tissue.

Drug Category
Antineoplastic Agents; ATC:L02BB03

Brand Names/Synonyms
Bicalutamide; Bicalutamide [Usan:Ban:Inn]; Casodex

Dosage Forms
TABLET

Absorption
Bicalutamide is well-absorbed following oral administration, although the absolute bioavailability is unknown.

Interactions
Interactions for Bicalutamide:

In vitro studies have shown CASODEX can displace coumarin anticoagulants, such as warfarin, from their protein-binding sites. It is recommended that if CASODEX is started in patients already receiving coumarin anticoagulants, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary.

Chemical IUPAC Name
N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methyl-propanamide

Chemical Formula
C18H14F4N2O4S

Half Life
5.9 days

Drug Type
Approved Drug

# Accession No
APRD00042

CAS Registry Number
90357-06-5